Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Part of paid clinical trials in Dublin, Ohio.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07024862
Status
Active Not Recruiting

Conditions

  • Metastatic Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

Key Dates

Start date
Oct 24, 2024
Status verified
Jun 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Cohort 1
    Adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

Primary Outcome Measure

Participant baseline socio-demographics [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cardinal HealthDublinOhio43017-

Find similar trials in Dublin, OH

By research site
Cardinal Health· Dublin, OH

Related Studies